Novel Population Pharmacokinetic Model for Linezolid in Critically Ill Patients and Evaluation of the Adequacy of the Current Dosing Recommendation
dc.contributor.author | Soraluce Olañeta, Amaia | |
dc.contributor.author | Barrasa González, Helena | |
dc.contributor.author | Asín-Prieto, Eduardo | |
dc.contributor.author | Sánchez Izquierdo, José Ángel | |
dc.contributor.author | Maynar, Javier | |
dc.contributor.author | Isla Ruiz, Arantxazu | |
dc.contributor.author | Rodríguez Gascón, Alicia | |
dc.date.accessioned | 2024-02-08T07:55:44Z | |
dc.date.available | 2024-02-08T07:55:44Z | |
dc.date.issued | 2020-01-09 | |
dc.identifier.citation | Pharmaceutics 12(1) : (2020) // Article ID 54 | es_ES |
dc.identifier.issn | 1999-4923 | |
dc.identifier.uri | http://hdl.handle.net/10810/64856 | |
dc.description.abstract | Antimicrobial treatment in critically ill patients remains challenging. The aim of this study was to develop a population pharmacokinetic model for linezolid in critically ill patients and to evaluate the adequacy of current dosing recommendation (600 mg/12 h). Forty inpatients were included, 23 of whom were subjected to continuous renal replacement therapies (CRRT). Blood and effluent samples were drawn after linezolid administration at defined time points, and linezolid levels were measured. A population pharmacokinetic model was developed, using NONMEM 7.3. The percentage of patients that achieved the pharmacokinetic/pharmacodynamic (PK/PD) targets was calculated (AUC24/MIC > 80 and 100% T>MIC). A two‐compartment model best described the pharmacokinetics of linezolid. Elimination was conditioned by the creatinine clearance and by the extra‐corporeal clearance if the patient was subjected to CRRT. For most patients, the standard dose of linezolid did not cover infections caused by pathogens with MIC ≥ | es_ES |
dc.description.sponsorship | This research was funded by Pfizer (012 ASPIRE EUMRSA _ Pharmacokinetic pharmacodynamic study of linezolid in critically ill septic patients undergoing continuous hemodiafiltration) and by the University of the Basque Country UPV/EHU (PPG17/65 and GIU17/32). | |
dc.language.iso | eng | es_ES |
dc.publisher | MDPI | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.subject | linezolid | es_ES |
dc.subject | population pharmacokinetics | |
dc.subject | critically ill | |
dc.subject | continuous renal replacement therapies | |
dc.subject | pharmacokinetic/pharmacodynamics | |
dc.subject | continuous infusion | |
dc.title | Novel Population Pharmacokinetic Model for Linezolid in Critically Ill Patients and Evaluation of the Adequacy of the Current Dosing Recommendation | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.rights.holder | © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). | |
dc.relation.publisherversion | https://www.mdpi.com/1999-4923/12/1/54 | |
dc.identifier.doi | 10.3390/pharmaceutics12010054 | |
dc.departamentoes | Farmacia y ciencias de los alimentos | es_ES |
dc.departamentoeu | Farmazia eta elikagaien zientziak | es_ES |
Files in this item
This item appears in the following Collection(s)
Except where otherwise noted, this item's license is described as © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).